Wortmannin

Catalog No.S2758 Synonyms: KY 12420

Wortmannin Chemical Structure

Molecular Weight(MW): 428.43

Wortmannin is the first described PI3K inhibitor with IC50 of 3 nM in a cell-free assay, with little selectivity within the PI3K family. Also blocks autophagosome formation and potently inhibits DNA-PK/ATM with IC50 of 16 nM and 150 nM in cell-free assays.

Size Price Stock Quantity  
USD 110 In stock
USD 170 In stock
USD 270 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

5 Customer Reviews

  • L3.6pl cells at 6,000 cells per well were incubated in MEM with 5% FBS in triplicate in a 96-well culture plate and then treated alone with 5 umol/L BMS-777607, 10 umol/L wortmannin, or with BMS-777607 in combination with individual inhibitors. Polyploidy was examined under BK71 Olympus microscope and photographed 72 hours after treatment.

    Mol Cancer Ther 2014 13(1), 37-48. Wortmannin purchased from Selleck.

    The effects of KITL on the differentiation of stem Leydig cells. Seminiferous tubules were cultured in the presence of various concentrations of KITL (K) without (C) or with PI3K inhibitor wortmannin (W) for 21 days. Panel A, KITL (0-100 ng/ml); Panel B, KITL (K) alone or with W (100 nM), K1 = KITL 1 ng/ml, K100 = 100 ng/ml. Medium testosterone (T) levels were measured. Mean ± SEM, n = 4-8. Identical letters indicate no significant difference between two groups at P < 0.05. W:Wortmannin

    Mol Cell Endocrinol, 2017, 444:1-8. Wortmannin purchased from Selleck.

  • Int J Mol Sci 2013 14(9), 17304-18. Wortmannin purchased from Selleck.

    Int J Mol Sci 2013 14(9), 17304-18. Wortmannin purchased from Selleck.

  • Cell growth inhibition of non-small cell lung carcinoma (NSCLC) by inhibitor of phosphoinositide 3-kinases (PI3Ks) Wortmannin. NCI-H460 and its multi-drug resistant (MDR) counterpart NCI-H460/R were subjected to Wortmannin. According to the results obtained, the effect of Wortmannin is dependent on the existence of MDR in the range of tested concentrations.

    2014 Dr.Milica Pesic from Institute for Biological Research. Wortmannin purchased from Selleck.

Purity & Quality Control

Choose Selective PI3K Inhibitors

Biological Activity

Description Wortmannin is the first described PI3K inhibitor with IC50 of 3 nM in a cell-free assay, with little selectivity within the PI3K family. Also blocks autophagosome formation and potently inhibits DNA-PK/ATM with IC50 of 16 nM and 150 nM in cell-free assays.
Targets
PI3K [3]
(Cell-free assay)
DNA-PK [12]
(Cell-free assay)
ATM [12]
(Cell-free assay)
MLCK [1]
(Cell-free assay)
ATR [12]
(Cell-free assay)
3 nM 16 nM 150 nM 170 nM 1.8 μM
In vitro

The inhibition of MLCK by Wortmannin is not affected by calmodulin or peptide substrat, while reduced by high concentration of ATP. Wortmannin directly interacts with the catalytic domain of MLCK and leads to an irreversible loss of the enzyme activity. Wortmannin has no inhibitory to cAMP-dependent protein kinase, cGMP-dependent protein kinase, and calmodulin-dependent protein kinase II, and has little effect on protein kinase C activity. [1] Wortmannin inhibits N-formylmethionyl-leucylphenylalanine (fMLP)-stimulated PtdInsP3 (phosphatidylinositol 3,4,5-trisphosphate) formation with IC50 of 5 nM and this inhibition is completely abolished when pretreated with 100 nM Wortmannin in human neutrophils, with increased PtdInsP2 levels and no effects on cellular PtdInsP and PtdIns contents. Wortmannin could develop oscillatory changes in F-actin content and does not inhibit fMLP-stimulated actin polymerization in neutrophils. [2] Wortmannin irreversibly inhibits phosphatidylinositol 3-kinase (PI3-kinase) activity with binding to the 110-kDa protein (IC50 of 3 nM) and has no effect PI4-kinase in RBL-2H3 cells. Wortmannin also inhibits both Fc epsilon RI-mediated histamine secretion and leukotriene release, with no effect on the activation of the tyrosine kinase Lyn. [3] Wortmannin completely abolishes the insulin-induced hexose uptake in isolated rat adipocytes at 0.1 μM, without impairing isoproterenol-stimulated lipolytic activity. [4] Wortmannin suppresses insulin-induced production of nitric oxide by 50% at 500 nM in human umbilical vein endothelial cells, which is in response to IGF-1. [5] Wortmannin suppresses DNA double strand break (DSB) repair and has no effect on DSB levels or the kinetics of single strand break (SSB) repair in Chinese hamster ovary cells at 50 μM. Wortmannin could potentiate ionizing radiation (IR)-induced cytotoxicity with no toxicity by itself. [6] Wortmannin inhibits polo-like kinase (PLK1) activity IC50 of 24 nM in intact G2/M-arrested cells. [7] Wortmannin increases Toll-like receptor (TLR)-mediated accumulation of IL-6 in human macrophages with EC50 of 50 nM. Meanwhile Wortmannin significantly enhances TLR-mediated inducible nitric-oxide synthase (iNOS) expression and nitrite accumulation in mouse macrphages. Wortmannin activates the nuclear factor-κB and up-regulates the cytokine mRNA production. [8] Wortmannin also inhibits Polo-like kinase (PlK) 1 and PlK3, which play important roles in mitosis. Wortmannin treatment could lead to a reduction in phosphorylation of p53 on serine 20 induced by DNA damage. [9] Wortmannin suppresses hyaluronan-induced Akt phosphorylation and cell motility/migration in SW1990 cells. [10]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
A459 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{\jWVIvPSEQvF2= MYSxMVQh\A>? M1TaXWROW09? NGXFS3VmdmijbnPld{Bk\WyuIHfyc5d1cCCrbnjpZol1cW:wIITy[YF1dWWwdDD3bZRpKHSjbX;4bYZmdg>? M2K3OVI2PDlyM{iz
H1703 NEftbppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYqyMlUh|ryP NIDWdFUyNTRiZB?= MV\EUXNQ M3viVYVvcGGwY3XzJINmdGxiZ4Lve5RpKGmwaHnibZRqd25idILlZZRu\W62IIfpeIghfGGvb4jp[oVv M4XVV|I2PDlyM{iz
HUVECs NGnGcFBEgXSxdH;4bYNqfHliQYPzZZk> NYjmdIxJOTByIH7N M4qzfFI1KGh? MV3heJRmdnWjdHXzJJRp\SCjYoLv[4F1cX[nIHXm[oVkfHNib3[gZ4FtgWOxc3nuJI9vKF[UST3pcoR2[2WmIHP5eI91d3irY3n0fS=> NXTGdpFHOjV2NUCxPFY>
APRE-19 NV3DS|BwSXCxcITvd4l{KEG|c3H5 MmHlOUDPxE1? NU[2R3FROjRiaB?= NHXaPHRi[m:uaYPo[ZMhTkycLX3l[IlifGWmIIDyc{1{fXK4aY\hcE9idnSrLXHwc5B1d3OrczDhZ5Rqfmm2eR?= NWjjSlB2OjV|Mkm2NVc>
MDA-MB-231 MVzBdI9xfG:|aYOgRZN{[Xl? MoTwNeKh|ryPwrC= NH:3R4g1QCCq M1HyW2ROW09? NHzKOohl\WO{ZXHz[ZMhfGinIHPlcIwhe3W{dnn2ZYwhfHKnYYTl[EB4cXSqIEK1JO69VSCxZjDGNUBweiCIMjFCpC=> M3XpU|I2OzByOUOy
MCF7 NGKzUG9HfW6ldHnvckBCe3OjeR?= NH\DOmcyODBibl2= MoXENlQhcA>? NFfi[llmdGmvaX7heIV{KEV{LXnu[JVk\WRiQWLFMWx2[yCjY4Tpeol1gQ>? MlvvNlUyPzJ3NUe=
HT-29  M1;ybGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1jsSlEvPcLiwsXN M2jQO|k3KGh? MnfQ[IVkemWjc3XzJINmdGxiZ4Lve5RpKHeqaXPoJINidiCkZTDpcohq[mm2ZXSgZpkhU1mQQR?= M{i1cVI2ODF{MUKz
MO59K  MlrER5l1d3SxeHnjbZR6KEG|c3H5 MmjhOeKh|ryP MnLuO{Bl NVXQToFNTE2VTx?= NGHPbm5mdmijbnPld{B1cGViY4n0c5RwgGmlaYT5JI9nKGW2b4Dvd4ll\SCxcjDjbZNxdGG2aX6= MXSyOFk2OzV4MR?=
MO59J MWrDfZRwfG:6aXPpeJkhSXO|YYm= MmfaOeKh|ryP NUTPOWZrPyCm NHjCOHlFVVOR MYHlcohidmOnczD0bIUh[3m2b4TvfIlkcXS7IH;mJIV1d3Cxc3nk[UBweiClaYPwcIF1cW5? M3\VSVI1QTV|NU[x
MO59K  NGS4T5RCeG:ydH;zbZMhSXO|YYm= Mmn2NVAh|ryP MkG3NlQhcA>? NUD3TmFTTE2VTx?= M32zfolv[3KnYYPld{B1cGViRGPCJIxmfmWuIHnu[JVk\WRiYomg[ZRweG:|aXTlJI9zKGOrc4DsZZRqdg>? NIHEXYMzPDl3M{W2NS=>
MO59J NFm0SHZCeG:ydH;zbZMhSXO|YYm= MkjwNVAh|ryP M4\4VVI1KGh? NFW3bJlFVVOR MoPsbY5kemWjc3XzJJRp\SCGU1KgcIV3\WxiaX7keYNm\CCkeTDleI9xd3OrZHWgc5Ih[2m|cHzheIlv M{TIWFI1QTV|NU[x
HepG2 M1HK[GZ2dmO2aX;uJGF{e2G7 MlLwNVAxKG6P M3rEVVAvPSCq MULEUXNQ M2DYSYJtd2OtczDNRU1qdmS3Y3XkJGFsfCCyaH;zdIhwenmuYYTpc44> NFjIVFQzPDh4M{O1NC=>
A549  NUfHfpV1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWOzJOK2VcLi M4fUeVIhcA>? MmXwd5VxeHKnc4Pld{Bx\W2ndILlfIVlNWmwZIXj[YQhSWu2IHHu[EBIW0t|zsKgZYN1cX[jdHnvckwhWy2yaHHz[UBienKnc4SsJINmdGxiYYDvdJRwe2m|IHHu[EBk[XOyYYPlMVMh[WO2aY\heIlwdg>? MmLrNlQ5PDd6NkO=
A549  M3nsPGZ2dmO2aX;uJGF{e2G7 MmLZNVDDqM7:bdMg MkfONVYhcA>? NEH1T|JFVVOR MX;tc4R2dGG2ZYOgeIhmKEmDVjDy[ZBtcWOjdHnvckBidmRiY3H1d4V{KHKndHXueIlwdiCxZjDOVEBqdiC2aHWgcpVkdGW3cz6= MWKyOFgxOjFzMR?=
SK-N-LO NW[1NlJsTnWwY4Tpc44hSXO|YYm= NYfkWJYyOTByIH7N NGnCR4kxNjViaB?= NFzZUY1l\WO{ZXHz[ZMhfGinIIP0bY12dGGwdDDl[oZm[3S|IH;mJI1wenCqaX7lJI9vKEGtdDDwbI9{eGixconsZZRqd25? MVuyOFY2PDZyNh?=
HL-60 NWS3fmMxTnWwY4Tpc44hSXO|YYm= MViwMlHDqM7:TR?= MYW3NkBp MVzicI9kc3NiZHHzZZRqdmmkLXnu[JVk\WRiY3XscEBlcW[oZYLlcpRq[XSrb36= NIHQS2czPDZyN{K3Ny=>
HepG2  NF7pTZdHfW6ldHnvckBCe3OjeR?= MnfINlAxKG6P M1PEc|AvPSCq NEO4PI9ifHSnboXheIV{KE[xeF:gdIhwe3Cqb4L5cIF1cW:w MVSyOFU{PTF7Mh?=
H520 M2jvR2Z2dmO2aX;uJGF{e2G7 MmHhNVDDqM7:TR?= Ml\JNUBp MoL3SG1UVw>? MUDk[YNz\WG|ZYOgZ4VtdHWuYYKgdIhwe3Cqbz3BT3QheHKxdHXpckBt\X[nbIO= MnvWNlQ1PDd7M{W=
H1975 MljYSpVv[3Srb36gRZN{[Xl? M2nTdVExyqEQvF2= NFPx[W8yKGh? MorlSG1UVw>? NXGzVHk4\GWlcnXhd4V{KGOnbHz1cIFzKHCqb4PwbI8uSUuWIIDyc5RmcW5ibHX2[Yx{ M1PoR|I1PDR5OUO1
MG-63 MUjBdI9xfG:|aYOgRZN{[Xl? MUexNEDDvU1? M1Sw[FEzKGh? MYrlcohidmOnczDEVE1qdmS3Y3XkJIFxd3C2b4Ppdy=> M3PmclI1OzV6M{Cx
5637 M13sN2Fxd3C2b4Ppd{BCe3OjeR?= NFTIdmIyOMLizszN NID0WHI1OCCvaX6= Mmm5doV3\XK|ZYOgdFIyX0GIMTDlfJBz\XO|aX;uMEBETEtiZYjwdoV{e2mxbjygZY5lKGOnbHygbY5pcWKrdHnvckBqdmS3Y3XkJIJ6KG[3Y3;p[IFv MVWyOFM{Ozh4OB?=
HEK-293 M{TETmZ2dmO2aX;uJGF{e2G7 NHGzdoYyPTCwTR?= MXSxOkBp M2\XbGROW09? M37MdoRm[3KnYYPld{BEWlRiYXP0bZZqfHl? NHnJRXgzPDN{NEO2Oi=>
SW480  MmXSSpVv[3Srb36gRZN{[Xl? NFf5RWUyPTCwTR?= MYKyNEBp NEfE[3NFVVOR NGDMOGpz\WS3Y3XzJINmdGy3bHHyJIFk[3WvdXzheIlwdiCxZjFOtk1k[XSnbnnu M1ywXVI1OzJ2M{[2
HepG2 NX\m[JRmTnWwY4Tpc44hSXO|YYm= M4nMeFExOCCwTR?= NYDQeGMzOjRiaB?= NG\WW21ifHSnboXheIV{KHSqZTDjc4xwdmmnczDv[kB1cGVidIXtc5Ih[2WubIOge4l1cCC3cILl[5Vt[XSrb36gc4YhSWu2MR?= MUKyOFI6PzVzMB?=
HCT 116  MVjGeY5kfGmxbjDBd5NigQ>? MWqxNFAhdk1? NF\vSJIzPCCq MY\heJRmdnWjdHXzJJRp\SClb3zvcolmeyCxZjD0bIUhfHWvb4KgZ4VtdHNid3n0bEB2eHKnZ4XsZZRqd25ib3[gRYt1OQ>? Mn3VNlQzQTd3MUC=
BEL/FU NGPWboRHfW6ldHnvckBCe3OjeR?= NVr0ZpRkOSCvTR?= M2DMflI1KGh? MUfk[YNz\WG|ZYOgdJJwfGWrbjDs[ZZmdHNib3[geIhmKFCLM1uvRYt1KHCjdHj3ZZk> MkjVNlQzOzJyOUm=
Huh7  MYHGeY5kfGmxbjDBd5NigQ>? MUezxsDPxE1? NHfCNlIyKGh? NIXBRYtz\WS3Y3XzJJRp\SC4aYL1d{BmdnS{eTDpcpRwKHSqZTDj[Yxtew>? NF3NSZYzPDF6NEG5Oi=>
A-375 MUHBdI9xfG:|aYOgRZN{[Xl? NE\LT2Y1NzhizszN MYiyOEBp MUXlcohidmOnczDUVmFKVC2rbnT1Z4VlKGGyb4D0c5Nqe8Li MmHjNlQyOTNzN{O=
A-375-TS  Ml;ORZBweHSxc3nzJGF{e2G7 NWX5TmpNPC96IN88US=> MWiyOEBp NEHCc4RmdmijbnPld{BVWkGLTD3pcoR2[2WmIHHwc5B1d3Orc9Mg NGCy[2wzPDFzM{G3Ny=>
Mel-HO MUfBdI9xfG:|aYOgRZN{[Xl? Mn;zOE85KM7:TR?= MXyyOEBp MWHlcohidmOnczDUVmFKVC2rbnT1Z4VlKGGyb4D0c5Nqe8Li NH3CdXUzPDFzM{G3Ny=>
Mel-HO-TS M{ns[2Fxd3C2b4Ppd{BCe3OjeR?= MmDjOE85KM7:TR?= NGPSOlkzPCCq NHu4c21mdmijbnPld{BVWkGLTD3pcoR2[2WmIHHwc5B1d3Orc9Mg M{jESFI1OTF|MUez
MeWo NHTyNllCeG:ydH;zbZMhSXO|YYm= NEnHNpg1NzhizszN NUHsdmJyOjRiaB?= NG\oVFVmdmijbnPld{BVWkGLTD3pcoR2[2WmIHHwc5B1d3Orc9Mg MkjqNlQyOTNzN{O=
Mel-2a MX;BdI9xfG:|aYOgRZN{[Xl? MorkOE85KM7:TR?= M3HtXFI1KGh? NVX1WZJw\W6qYX7j[ZMhXFKDSVytbY5lfWOnZDDhdI9xfG:|aYRCpC=> NGLzT5MzPDFzM{G3Ny=>
MDA-MB-231 MnP2SpVv[3Srb36gRZN{[Xl? NX;oNVhtOOLCk{SwNEBvVQ>? NEL2UJE1KGh? MUnzeZBxemW|c3XzJGFsfCCyaH;zdIhwenmuYYTpc44hcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> MnfaNlI6ODZ{NUm=
MDA-MB-231 M{PMbGZ2dmO2aX;uJGF{e2G7 NI\nXno1ODBibl2= NGf4ZXk1KGh? MlWy[IVkemWjc3XzJG1OWC17IHHu[EBKVC16IIDyc5RmcW5iaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? MXqyNlkxPjJ3OR?=
Jurkat NVLRNFM5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF7aclYxNjJ3LUGuNlUh|ryP NYHmd5k5OjRxNEigbC=> NXnMfnBOTE2VTx?= MoWxbY5pcWKrdIOgZ4VtdCCycn;sbYZmemG2aX;uJIlvKGKxdHigeIlu\S1iYX7kJIRwe2VvIHTldIVv\GWwdDDtZY5v\XJ? M2XGblE6PzV5MUi1
Namalwa MnywS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NETxU|kxNjJ3LUGuNlUh|ryP M13NVVI1NzR6IHi= NWfOcW4{TE2VTx?= MUTpcohq[mm2czDj[YxtKHC{b3zp[oVz[XSrb36gbY4h[m:2aDD0bY1mNSCjbnSg[I9{\S1iZHXw[Y5l\W62IH3hco5meg>? MXyxPVc2PzF6NR?=
Jurkat MojxRZBweHSxc3nzJGF{e2G7 MWSwMlI2NTFwMkWg{txO MoPrNlQwPDhiaB?= NFXvOmRFVVOR M1q5V4lv\HWlZYOgZ4VtdCCjcH;weI9{cXNiaX6gZo91cCC2aX3lMUBidmRiZH;z[U0h\GWyZX7k[Y51KG2jbn7ldi=> Moe4NVk4PTdzOEW=
Namalwa NXTnfHpYSXCxcITvd4l{KEG|c3H5 M3vhclAvOjVvMT6yOUDPxE1? MmrnNlQwPDhiaB?= M4TWTmROW09? NHTSR4dqdmS3Y3XzJINmdGxiYYDvdJRwe2m|IHnuJIJwfGhidHnt[U0h[W6mIHTvd4UuKGSncHXu[IVvfCCvYX7u[ZI> NX[y[IdYOTl5NUexPFU>
K562 NUPZOYRET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVyyOEBp M2XYXGlEPTB;MkZCtVAvOTRibl2= M4DUWFE6PjZ{M{[x
SW1990 MXHGeY5kfGmxbjDBd5NigQ>? NYfnO|VIOC5yMT2xJO69VQ>? NXnqdINVOSCq NVvMc5pvcW6qaXLpeJMhUEFvaX7keYNm\CCDa4SgdIhwe3Cqb4L5cIF1cW:w MWOxPVQ3QTB{MB?=
RT112  NWjjNmJqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXPYZY01OTEEoN88US=> NVOwfXE4OjRiaB?= Mn21SG1UVw>? M3uzXoRm[3KnYYPld{B1cGVicILvdI9zfGmxbjDv[kBIOi:PIHPlcIx{ MnvaNVg4QDd6M{K=
MHG-U1 NF7SRllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF7HXlgyOMLizszN MV[yOEBp NHvid4pFVVOR NUnN[|ZP\GWlcnXhd4V{KHSqZTDwdo9xd3K2aX;uJI9nKEd{L12gZ4VtdHN? NEjTPI4yQDd6N{izNi=>
SMMC-7721 MULBdI9xfG:|aYOgRZN{[Xl? NUPzTGg6OjBywrDuUS=> M4XVeVI1KGh? MWLpcoNz\WG|ZYOgR2hZNWmwZIXj[YQh[XCxcITvd4l{ M{XUTFE4PTV5MUmx
SMMC-7721 MlvqSpVv[3Srb36gRZN{[Xl? MV:yNFDDqG6P NYrYZnk1OjRiaB?= M3Sxc5VxNXKnZ4XsZZRmeyEQskGsOGdVOSCneIDy[ZN{cW:w NX\VXmNnOTd3NUexPVE>
HeLa MV3GeY5kfGmxbjDBd5NigQ>? M4XwbVExOMLibl5CpC=> MnvCNUBp NG\xTGVidHSncoOgeIhmKG2xcoDoc4xw\3lib3[geIhmKHS{YX7z[oVzemmwIILlZ5lkdGmwZzDjc41x[XK2bXXueC=> NEGyUHIyPjh7MEmxOS=>
MRC5VI NGPWO3lHfW6ldHnvckBCe3OjeR?= Mnf0NVIvPSCvTR?= NVzYOpQxOC53IHi= M{XwdmROW09? NYf5TpE2[WKxbHnzbIV{KHSqZTDT[ZI1PzNxVHjyN|A5yqCyaH;zdIhwenmuYYTpc44hd2ZiQXv0VGtDyqB? Mn;pNVYzOjd|OUS=
AT5BIVA M33PbGZ2dmO2aX;uJGF{e2G7 MnXvNVIvPSCvTR?= M{\UdFAvPSCq MWTEUXNQ Mn\SZYJwdGm|aHXzJJRp\SCVZYK0O|MwXGi{M{C4xsBxcG:|cHjvdplt[XSrb36gc4YhSWu2UFvCxsA> M4jmZVE3OjJ5M{m0
M059J MlqwSpVv[3Srb36gRZN{[Xl? NYOzbVhsOTJwNTDtUS=> MWWwMlUhcA>? MVrEUXNQ MYLhZo9tcXOqZYOgeIhmKFOnckS3N{9VcHJ|MElCpJBpd3OyaH;yfYxifGmxbjDv[kBCc3SSS1NCpC=> NELKZncyPjJ{N{O5OC=>
HeLa Mn7pSpVv[3Srb36gRZN{[Xl? NF\aR4YyOi53IH3N NYXXSXd{OC53IHi= M2e0R2ROW09? NUDWfJl{[WKxbHnzbIV{KHSqZTDT[ZI1PzNxVHjyN|A5yqCyaH;zdIhwenmuYYTpc44hd2ZiQXv0VGtDyqB? Mn7wNVYzOjd|OUS=
N2a MmH2RZBweHSxc3nzJGF{e2G7 MkjENE4yNTFyIN88US=> Mle0NkBp M3zWZYlv\HWlZYOg[IVkemWjc3XkJINmdGxidnnhZoltcXS7IHnuJIEh[2:wY3XueJJifGmxbj3k[ZBmdmSnboSgcYFvdmW{ NGXZb20yPTh2Mke2Oy=>
Jurkat  NITmeHdMcW6jc3WgRZN{[Xl? M3\HT2lEPTBib3[gNlQhdk1? M1XGOFE2PjZ2NUG5

... Click to View More Cell Line Experimental Data

In vivo Wortmannin inhibits peritoneal metastasis of SW1990 in mice at 1 mg/kg, without any weight loss. [10] Wortmannin inhibits phosphatidylinositide 3-kinase-protein kinase B (PKB)/Akt phosphorylation in both normal tissues (lung, heart and brain homogenates) and tumor tissue in mice, without mortality or acute toxicity at 0.7 mg/kg. Combination with LY188011, Wortmannin significantly increases apoptosis and inhibit tumor growth in orthotopic tumor, while both monotherapy could not. [11]

Protocol

Animal Research:[11]
+ Expand
  • Animal Models: Human pancreatic adenocarcinoma cells PK1 are injected both s.c. and orthotopically into SCID mice.
  • Formulation: Dissolved at 0.4 mg/mL in DMSO, and diluted with 0.9% NaCl before use
  • Dosages: 0.175, 0.35, and 0.7 mg/kg
  • Administration: Injected by i.v.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 85 mg/mL (198.39 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents individually and in order:
5%DMSO+corn oil
11mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 428.43
Formula

C23H24O8

CAS No. 19545-26-7
Storage powder
Synonyms KY 12420

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

PI3K Signaling Pathway Map

PI3K Inhibitors with Unique Features

Related PI3K Products

Tags: buy Wortmannin | Wortmannin supplier | purchase Wortmannin | Wortmannin cost | Wortmannin manufacturer | order Wortmannin | Wortmannin distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID